Get App
Market Opening - An Overview
Nifty futures on the Singapore Exchange were trading 0.42% higher at 17,785.50, indicating that Dalal Street was headed for a positive start on Monday.
Most major Asian stock indices were trading lower as traders were keeping an eye on monetary policy plans by central banks amid rising global inflation. Japan’s Nikkei was down 0.23% and Topix fell 0.34%. Hang Seng lost 0.27%, while CSI 300 was up 0.32%.
Indian rupee inched up 4 paise to close at 74.24 against the US dollar on Thursday.
FII/DII Trading Data on Thursday (18-11-2021)
| Category | Buy Value | Sell Value | Net Value |
| FII/FPI | 8781.77 | 12712.39 | (3930.62) |
| DII | 6846.1 | 4960.44 | 1885.66 |
| *All numbers are in INR crore | |||
Stocks in News Today
Maruti Suzuki: The carmaker will not produce diesel cars as the company expects markets for such vehicles would further come down with the onset of the next phase of emission norms in 2023, according to C V Raman, Chief Technical Officer of the company. It believes the stricter emission norms would increase the cost of diesel vehicles.
State Bank of India: The country’s biggest lender is yet to return Rs 164 crore of undue fee charged from the account holders of Pradhan Mantri Jan Dhan Yojana (PMJDY) towards digital payments during April 2017 and December 2019, according to a report IIT-Mumbai. It said that between April 2017 to September 2020, SBI had collected over Rs 254 crore from at least 14 crore UPI/ RuPay transactions by charging Rs 17.70 per transactions on BSBDA customers under the Pradhan Mantri Jan Dhan Yojana.
Punjab National Bank: The lender’s 18 crore customers’ personal and financial details have been exposed for seven months due to a security issue in its servers, according to CyberX9, a cyber security firm. The bank has confirmed about the glitch but denied any exposure of critical data due to the vulnerability.
Laurus Labs: The company has signed an investment deal with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company, to acquire a 26.62 per cent stake (fully diluted basis) for ₹46 crore. The deal is subject to the fulfilment of certain conditions. Additionally, the company’s senior management would also invest in ImmunoACT for a 5.64 per cent stake for approximately ₹9.75 crore at same price and terms, according to a stock exchange filing.
Sun Pharmaceutical: The drugmaker is recalling over 1.10 lakh bottles of a generic medication used to treat erectile dysfunction in men in the US market due to a manufacturing defect. The recall of Tadalafil tablets in the American market is according to the latest enforcement report of the US Food and Drug Administration.
IRB Infrastructure Developers: The company’s shareholders have passed a resolution which will enable the company to raise capital Rs 5,347 crore. The company will issue shares to the tune of Rs 5,347 crore to the Cintra Global S.E. (a wholly owned subsidiary of Ferrovial S.A) and the Bricklayers Investments Pt. Ltd. (an affiliate of GIC, Singapore Sovereign wealth fund), IRB said.
Zydus Cadila: The pharma company has received an approval from the US health regulator Food and Drug Administration to market Decitabine injection, used to treat certain types of cancers, in the American market. The drug will be produced at the group’s injectables manufacturing facility, Cadila said.
Sundaram Finance: The company’s subsidiary Sundaram AMC said it has received the regulatory approval to acquire the asset management businesses of Principal Asset Management Pvt Ltd. Sundaram Finance Executive Vice Chairman Harsha Viji said that the acquisition is a natural step in their aspiration to become a sizable player in the asset management industry.